Transgene Announces Upcoming Investor Meetings
21 Décembre 2023 - 5:45PM
Business Wire
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management
will participate in several investor events in the upcoming
investor events, as set out below.
Transgene will meet institutional investors at the 13th
Annual LifeSci Advisors Corporate Access Event in San Francisco
from January 8 to 10, 2024, in conjunction with the J.P. Morgan
Healthcare conference.
The Company will also attend:
- 27th ODDO BHF Forum (virtual): January 15-16, 2024;
- Invest Securities Biomed Forum (Paris): January 30,
2024.
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.fr Follow us on social
media: X (ex-Twitter): @TransgeneSA – LinkedIn: @Transgene
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221837207/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting Frazer Hall/Sylvie Berrebi
+44 (0)203 928 6900 transgene@medistrava.com
Transgene (EU:TNG)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Transgene (EU:TNG)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024